Publication:
Comparative Outcome of Reduced Intensity and Myeloablative Conditioning Regimen in HLA Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia Patients: A Single Center Experience

dc.contributor.authorGoker, Hakan
dc.contributor.authorOzdemir, Evren
dc.contributor.authorUz, Burak
dc.contributor.authorBuyukasik, Yahya
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorSerefhanoglu, Songul
dc.contributor.authorOzcebe, Osman I.
dc.contributor.authorIDHaznedaroglu, Ibrahim C./0000-0001-8028-9462
dc.contributor.authorIDBayram, Cem/0000-0001-8717-4668
dc.date.accessioned2020-06-21T14:04:13Z
dc.date.available2020-06-21T14:04:13Z
dc.date.issued2013
dc.departmentOMÜen_US
dc.department-temp[Goker, Hakan -- Uz, Burak -- Buyukasik, Yahya -- Serefhanoglu, Songul -- Aksu, Salih -- Sayinalp, Nilgun -- Haznedaroglu, Ibrahim C.en_US
dc.description.abstractDue to the high transplant related morbidity and mortality (TRM), relatively younger acute leukemia patients that have a good performance status and no comorbidity are eligible for myeloablative conditioning (MAC) followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). The outcomes of 84 consecutive adult patients with ALL (n = 38) or AML (n = 46) who underwent allo-HSCT from their HLA-identical siblings were evaluated retrospectively. The median age at transplantation was 34 (17-58 years) for the whole patient population. Of these, 24 patients received a MAC and 60 patients received a fludarabine-based reduced intensity conditioning regimen (RIC). After a median follow-up of 32 months (range, 1-119), for the entire group, the 3-year estimated overall survival (OS) was 57.5% and the disease-free survival (DFS) was 51.5%. The OS for ALL and AML patients were 53.9% vs 62.1%; and DES were 50.5% and 53.4%, respectively. The 3-year estimated OS for RIC and MAC patients were 63.2% and 41.7%; and DFS were 57.1% and 34.7%, respectively. In ALL patients, conditioning regimens (RIC vs MAC) led to similar OS and DFS; however, in AML patients both OS (70.1% vs 21.4%) and DFS (59.3% vs 42.9%) were found to be higher in RIC patients compared to MAC recipients. Overall, the TRM at day 100 was 1.7% and has increased up to 5.1% at 1st year. In multivariate analysis, the diagnosis (p = 0.03) and RIC regimen (p = 0.027) were the prognostic variables for prolonged OS in all patients; and RIC regimen (p = 0.031) was the only prognostic factor for prolonged OS in AML patients. The first complete remission (CR1) was correlated with a prolonged DFS as an independent variable for all patients (p = 0.09). Eleven of the RIC patients (18.3%) and 6 of the MAC patients (25%) developed acute graft-versus-host disease (GvHD). Seventeen of the RIC patients (33.3%) and 4 of the MAC patients (16.7%) developed chronic GvHD. In conclusion, RIC conditioning regimens may provide a longer OS and DFS, especially in patients with AML who are in first CR, not eligible for MAC conditioning. (C) 2013 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.transci.2013.07.030
dc.identifier.endpage599en_US
dc.identifier.issn1473-0502
dc.identifier.issue3en_US
dc.identifier.pmid23981652
dc.identifier.startpage590en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2013.07.030
dc.identifier.urihttps://hdl.handle.net/20.500.12712/15566
dc.identifier.volume49en_US
dc.identifier.wosWOS:000329012500044
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.journalTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectReduced Intensity Conditioning Regimenen_US
dc.subjectMyeloablative Conditioning Regimenen_US
dc.subjectAllogeneic Hematopoietic Stem Cell Transplantationen_US
dc.subjectGraft-Versus-Host Diseaseen_US
dc.titleComparative Outcome of Reduced Intensity and Myeloablative Conditioning Regimen in HLA Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia Patients: A Single Center Experienceen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files